Document Classification

Section Type: RESULTS

Text: Among patients who received cladribine tablets (either 3. 5 mg or 5. 25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group (0. 14 and 0. 15, respectively, vs. 0. 33 ; P < 0. 001 for both comparisons), a higher relapse-free rate (79. 7 % and 78. 9 %, respectively, vs. 60. 9 % ; P < 0. 001 for both comparisons), a lower risk of 3-month sustained progression of disability (hazard ratio for the 3. 5-mg group, 0. 67 ; 95 % confidence interval [CI], 0. 48 to 0. 93 ; P = 0. 02 ; and hazard ratio for the 5. 25-mg group, 0. 69 ; 95 % CI, 0. 49 to 0. 96 ; P = 0. 03), and significant reductions in the brain lesion count on magnetic resonance imaging (MRI) (P < 0. 001 for all comparisons).